Madrigal Pharmaceuticals announced an exclusive global licensing agreement with Suzhou Ribo Life Science for six preclinical siRNA programs to expand its MASH treatment pipeline. The deal includes a $60 million upfront payment with potential cumulative payments reaching $4.4 billion upon milestone achievement. Madrigal's pipeline now includes over 10 programs anchored by its approved drug Rezdiffra, with additional candidates including MGL-2086 (GLP-1 agonist) and Ervogastat (DGAT-2 inhibitor) in development.

Ten large-cap stocks experienced significant declines during the week of January 5-9, 2026. Notable losers include Madrigal Pharmaceuticals (down 11.57%), First Solar (down 14.46% following a Jefferies downgrade), Astera Labs (down 12.18%), and Roblox (down 9.99%). Other major decliners include CoStar Group, American International Group, NRG Energy, Las Vegas Sands, Johnson Controls International, and HDFC Bank. The declines were driven by analyst downgrades, leadership transitions, and executive changes.

Madrigal Pharmaceuticals announced an exclusive global license agreement with Pfizer to develop ervogastat, a Phase 2 oral DGAT-2 inhibitor for MASH treatment. The deal includes a $50 million upfront payment to Pfizer, with ervogastat positioned as a complementary therapy to Madrigal's approved drug Rezdiffra for potential combination treatment. Madrigal plans to conduct drug-to-drug interaction studies and consult with the FDA on Phase 2 combination trial design in 2026.

The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.

Novo Nordisk faces challenges in 2026 but shows potential for recovery through lower drug prices, new drug indications, and promising pipeline candidates like Amycretin, which could help stabilize revenue growth.

Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.

Madrigal Pharmaceuticals presented two-year data on Rezdiffra, demonstrating significant improvements in liver imaging tests and biomarkers for patients with compensated MASH cirrhosis, highlighting potential benefits across different patient populations.

Recent insider trading activities reveal interesting signals for CoreWeave and Madrigal Pharmaceuticals. While CoreWeave insiders are selling shares after a significant stock price increase, Madrigal insiders are buying, signaling potential opportunities in AI infrastructure and biotech sectors.

Madrigal Pharmaceuticals reported strong Q2 2025 performance, with GAAP revenue of $212.8 million for its MASH therapy Rezdiffra, exceeding estimates by 31.3%. The company saw rapid patient adoption, with over 23,000 patients on the drug and expanding commercial operations.

Madrigal Pharmaceuticals will release its Q2 2025 financial results on August 5, 2025, and host a live webcast at 8 a.m. Eastern Time to review financial and operating results.

Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra, demonstrating significant improvements in liver stiffness, liver fat, fibrosis biomarkers, liver volume, and risk scores for clinically significant portal hypertension.

Madrigal Pharmaceuticals, a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), will release its Q1 2025 financial results and host a webcast on May 1, 2025.